Overview
Olivier has served as CEO of IBA since 2012. He graduated from the Vrije Universiteit Brussel in 1992 and built his career in the medical device and proton therapy sector. Before becoming CEO, he was Chief Strategy Officer at IBA Molecular Holding from 2003 to 2010, and prior to that served as CEO of Scanditronix Medical (2001 to 2003).
Under his leadership, IBA has strengthened its position as the global reference point for proton therapy systems and dosimetry solutions. The company serves cancer treatment centers worldwide and has expanded into carbon therapy and other advanced radiation modalities. IBA founder Yves Jongen remains connected to the company he created in 1986.
Career Highlights
- CEO of IBA since 2012, maintaining the company's position as global proton therapy market leader
- Former CEO of Scanditronix Medical2001 to 2003former CSO of IBA Molecular Holding (2003 to 2010)
- Oversaw IBA's launch of the Proton Therapy Academy in partnership with leading global cancer centers
Career history
Insights & ideas
The through-line
Across Olivier Legrain's public statements, one idea keeps resurfacing: that IBA's work is not really about technology, it is about care. He repeatedly frames the company's projects, from proton therapy centers to the Oncia Community's patient houses, as expressions of a deeper mission "to accelerate the development of ce type de maison" that helps patients keep "la joie de vivre dans la peur de mourir" [3]. Over time this preoccupation has moved from being an implicit backdrop to product launches toward an explicit philosophy of the firm, one where he argues a company's purpose extends "far beyond short-term profit maximization" and must account for responsibility toward employees, society and the environment [15]. The shift is also organizational: as IBA marks 40 years and grows to a global scale, Legrain describes reshaping his own role and the leadership team so he can "focus deeply on the strategic steering of the Group" while trusting others with operations [6].
On humanizing cancer care
Legrain consistently describes IBA's innovations, and especially its Oncia Community initiative, as evidence that "technology alone isn't enough" [8]. He calls the effort "one of the most important innovation in cancer care. Humanizing cancer care" [4], and ties it to a moral obligation: "Nous avons l'obligation morale d'accélérer le développement de ce type de maison" [3]. He credits the people driving this vision directly, praising "Gauthier Saelens pour sa vision et sa determination" [3] and expressing eagerness to advance the cause alongside "mon cher ami Renaud" for "une cause qui nous tient tous les deux très a coeur" [13].
On purpose beyond profit
In his L'Echo podcast appearance, Legrain lays out his clearest statement of corporate philosophy: a company "is much more than profit maximization" and must weigh medium and long-term thinking rather than fixate on stock price, which he argues lets companies "manage risks better, attract talent, and create value for stakeholders while still generating profit" [15]. This framing runs underneath his written posts as well, where pride is repeatedly tied not to financial results but to people and mission, as when he says the company's 40th anniversary "reminded me that our mission is only possible because of the people behind" it [10].
On community and shared learning
Legrain treats professional gatherings and partnerships as engines of progress, not just networking. At Amstro he emphasized that a small, high-quality conference "create[s] community among practitioners, enabling faster learning, knowledge sharing, and quicker adoption of best practices in radiation oncology" [16]. He extends the same logic to IBA's customer and institutional relationships, describing a proton therapy event as gathering "a vibrant community" of "luminaries delivering the promise of Proton Therapy to thousands of patients around the world" [12], and thanking long-term partners like Kazakhstan's Institute of Nuclear Physics for "continued trust" built over "a decade of successful collaboration" [5].
From the stage
In interviews, Legrain covers ground his written posts do not: the origin story of IBA itself, tracing its founding to when its creator "left UCL's cyclotron laboratory to start IBA across the street," and situating the company's growth to "2,300 employees and 500 million euros in annual revenue" over a 40-year arc [14]. He also articulates, more fully than in any post, his argument against short-term profit maximization as a governing logic for companies, explicitly linking medium and long-term thinking to risk management and talent attraction [15]. And at Amstro he speaks to the mechanics of professional learning, that small-scale conferences enable "quality interactions with interesting people and sessions" and speed the adoption of best practices in a way large events do not [16].
Takeaways
- Legrain frames Oncia Community and similar patient-support projects as a moral obligation, not a side initiative, because they measurably increase "chances de rémission" [3].
- He explicitly rejects profit maximization as a company's core purpose, arguing medium and long-term thinking better manages risk and attracts talent [15].
- IBA's recent leadership restructuring, expanding Henri de Romrée and Catherine Vandenborre's roles, was designed to free Legrain to concentrate on strategic steering rather than operations [6].
- He values small, focused industry conferences over large ones for accelerating knowledge-sharing and best-practice adoption among practitioners [16].
- Long-standing partnerships, like IBA's decade-long collaboration with Kazakhstan's Institute of Nuclear Physics, are presented as proof points of trust and sustained capability-building [5].
- IBA's 40th anniversary is used by Legrain to credit the company's people, not its technology, as the source of its mission's success [10].
Media & appearances
- AMSTROYouTubeInterview - Mr. Olivier LegrainOlivier Legrain, CEO of IBA, discusses his experience at the inaugural Amstro conference, noting that the small meeting size allowed for quality interactions with interesting people and sessions. He highlights the industry discussion about regional development commitment and a session on MRI use for liver treatment as particularly valuable. Legrain emphasizes that such conferences create community among practitioners, enabling faster learning, knowledge sharing, and quicker adoption of best practices in radiation oncology.
- Le Trends Talk avec Olivier Legrain, CEO d'IBA dans Z sur 7 · Trends Podcasts: # Summary Olivier Legrain discusses IBA's 40-year journey from a university laboratory spinoff to a global company with 2,300 employees and 500 million euros in annual revenue, tracing its founding when the company's creator left UCL's cyclotron laboratory to start IBA across the street.
- L'EchoYouTubePodcast | 7. "Une entreprise, c’est bien plus que la maximisation des profits", Olivier Legrain(IBA)Olivier Legrain discusses how a company's purpose extends far beyond short-term profit maximization and must account for responsibility toward employees, society, and the environment. He argues that introducing medium and long-term thinking, rather than focusing solely on stock price, allows companies to manage risks better, attract talent, and create value for stakeholders while still generating profit.
In the news
- On my way back to Europe from the incredible new airport of Guwahati. Incredible infrastructure development under the leadership of the Honorable Chief Minister Himanta Biswa Sarma . Could be a nice inspiration for Brussels Airport :-).
- Au travail
- Proton therapy is an extraordinary technology. But technology alone is not enough. Delivering the full potential of proton therapy requires highly trained teams, continuous learning, and the ability to respond effectively when the unexpected happens. Training should therefore not stop when a proton therapy center becomes operational. It needs to remain part of how we continuously improve patient care, clinical performance and operational excellence. This is exactly why we created the Proton Therapy Academy: to help the proton therapy
- FR: "L'actuelle exposition renouvelle totalement le champ d'investigation de #PhilippeDeGobert et annonce dès le choix de son titre Dedans / Dehors une rupture autant stylistique qu'artistique avec l'ensemble de recherches antérieures. Ces photographies sont exposées sans encadrement apparent. Contrairement aux précédentes, tout en conservant la même rigueur de propos, les différentes Dedans qu'elles proposent à nos regards ne présentent plus que quelques rares allusions aux travaux antérieurs qui auraient pu y être menés. C'est
- a very inspiring project. Looking forward to our collaboration.
- A strategic step forward for IBA in the fight against cancer. Radioligand therapies, and particularly targeted alpha therapies, have the potential to become a game changer in precision oncology. But fulfilling that potential requires one critical element: reliable, scalable and industrial production of therapeutic isotopes. This is where IBA can make a difference. With our expertise in particle accelerators and radiopharmaceutical production, we are strategically expanding our contribution from diagnosis to therapy, helping build
- What a great news. Congratulations team.
- I fully agree with you Andrew Dike. It was really eye-opening. Congratulations to all involved.
Related profiles
This page shows public professional information only, each fact cited. Is this you? send a correction, or ask for removal within 24 hours, no questions asked.